Therapeutic Areas: Oncology | Hematology | Musculoskeletal

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Alabama

NEW

Research Center
Additional Locations Alabama

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Arizona

NEW

Research Center
Additional Locations Arizona

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Tucson Arizona 85724

A clinical research study for the treatment of Acute Myeloid Leukemia

UPDATED

Tucson Arizona 85719

A clinical research study for the treatment of Acute Myeloid Leukemia

Arkansas

NEW

Research Center
Additional Locations Arkansas

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

California

NEW

Research Center
Additional Locations California

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

La Jolla California 92093

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Los Angeles California 90033

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Los Angeles California 90095

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Los Angeles California 90095

A clinical trial to evaluate treatments using MEDI7247 for patients with Acute Myeloid Leukemia, Multiple Myeloma or Diffuse Large B-cell Lymphoma

Colorado

NEW

Research Center
Additional Locations Colorado

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Aurora Colorado 80045

A clinical trial seeking patients for a Cancer treatment research study

UPDATED

Denver Colorado 80218

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Denver Colorado 80218

A clinical trial to evaluate treatments using MEDI7247 for patients with Acute Myeloid Leukemia, Multiple Myeloma or Diffuse Large B-cell Lymphoma

Connecticut

NEW

Research Center
Additional Locations Connecticut

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

New Haven Connecticut 06520

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

Delaware

NEW

Research Center
Additional Locations Delaware

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

District of Columbia

NEW

Research Center
Additional Locations District of Columbia

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Washington District of Columbia 20037

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

Florida

NEW

Research Center
Additional Locations Florida

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Georgia

NEW

Research Center
Additional Locations Georgia

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Atlanta Georgia 30342

A clinical trial to evaluate treatments using Alvocidib, Cytarabine and Mitoxantrone for patients with Acute Myeloid Leukemia (AML)

Hawaii

NEW

Research Center
Additional Locations Hawaii

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Idaho

NEW

Research Center
Additional Locations Idaho

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Illinois

NEW

Research Center
Additional Locations Illinois

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Chicago Illinois 60637

A clinical research study for the treatment of Acute Myeloid Leukemia

UPDATED

Chicago Illinois 60637

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Chicago Illinois 60611

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Niles Illinois 60714

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

Indiana

NEW

Research Center
Additional Locations Indiana

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Indianapolis Indiana 46237

A clinical research study of guadecitabine and Treatment Choice (TC) for the treatment of Acute Myeloid Leukemia

UPDATED

Indianapolis Indiana 46237

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Indianapolis Indiana 46237

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

Iowa

UPDATED

Iowa City Iowa 52242

A clinical trial to evaluate treatments using Alvocidib, Cytarabine and Mitoxantrone for patients with Acute Myeloid Leukemia (AML)

UPDATED

Sioux City Iowa 51101

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

Kansas

UPDATED

Westwood Kansas 66205

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Westwood Kansas 66205

A clinical trial to evaluate treatments using Alvocidib, Cytarabine and Mitoxantrone for patients with Acute Myeloid Leukemia (AML)

Kentucky

NEW

Research Center
Additional Locations Kentucky

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Louisville Kentucky 40207

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Louisville Kentucky 40207

A Phase 3 clinical study for patients with Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) or Leukemia, Myeloid, Acute

Louisiana

NEW

Research Center
Additional Locations Louisiana

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Covington Louisiana 70433

A clinical research study of Pracinostat, Placebos and Azacitidine for the treatment of Acute Myeloid Leukemia

UPDATED

New Orleans Louisiana 70112

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

New Orleans Louisiana 70121

A clinical trial to evaluate treatments using Alvocidib, Cytarabine and Mitoxantrone for patients with Acute Myeloid Leukemia (AML)

Maine

NEW

Research Center
Additional Locations Maine

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

Maryland

NEW

Research Center
Additional Locations Maryland

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD

UPDATED

Baltimore Maryland 21231

A clinical trial seeking patients for a research study for the treatment of Acute Myeloid Leukemia

UPDATED

Baltimore Maryland 21287

A clinical trial to evaluate treatments using Alvocidib, Cytarabine and Mitoxantrone for patients with Acute Myeloid Leukemia (AML)

UPDATED

Bethesda Maryland 20187

A clinical research study of Pracinostat, Placebos and Azacitidine for the treatment of Acute Myeloid Leukemia

Massachusetts

NEW

Research Center
Additional Locations Massachusetts

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD